Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 4/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10057698 | 0.86 | HRH3 (0.45) | PDE9AACACBLIPGGRIN1GRIN2B | |
| SCHEMBL20147887 | 0.85 | PDE9A (0.43) | PDE9AACACBHRH3 | |
| SCHEMBL22857080 | 0.83 | PDE9A (0.44) | PDE9AACACBLIPG | |
| SCHEMBL20205885 | 0.78 | SLC6A4 (0.43) | PDE9AGRIN1GRIN2B | |
| SCHEMBL23993214 | 0.78 | HRH3 (0.55) | LIPGHRH3 | |
| SCHEMBL10057700 | 0.78 | HRH3 (0.55) | LIPGHRH3 | |
| SCHEMBL20158435 | 0.78 | HSD11B1 (0.47) | PDE9ASLC6A3GRIN1GRIN2B | |
| SCHEMBL10078847 | 0.77 | HTR2C (0.47) | LIPGGRIN1GRIN2BHRH3EPHX2 | |
| SCHEMBL21004282 | 0.75 | HRH3 (0.47) | LIPGHRH3 | |
| SCHEMBL795699 | 0.74 | ACHE (0.45) | GRIN1GRIN2BSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | PDE9A 1154/4885ACACB 4835/4885LIPG 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.